Repligen Corporation $RGEN Stake Trimmed by Jefferies Financial Group Inc.

Key Points

• Jefferies Financial Group cut its Repligen stake by 99.9% in the third quarter, selling 5,659,497 shares and retaining 5,503 shares valued at about $1.06 million.
• Analysts hold a “Moderate Buy” consensus on Repligen, with an average price target of $178.57; recent ratings include both price-target increases and a downgrade to Sell.
• Repligen beat quarterly estimates, reporting EPS of $0.53 versus $0.46 expected and revenue of $209.31 million, up 10.9% year over year.

Jefferies Financial Group Inc. lowered its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 99.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,503 shares of the biotechnology company's stock after selling 5,659,497 shares during the period. Jefferies Financial Group Inc.'s holdings in Repligen were worth $1,058,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. United Capital Financial Advisors LLC bought a new position in shares of Repligen during the second quarter worth approximately $380,756,000. Wasatch Advisors LP boosted its stake in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after buying an additional 346,720 shares during the period. Congress Asset Management Co. boosted its stake in shares of Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company's stock valued at $196,249,000 after buying an additional 8,681 shares during the period. ABS Investment Management LLC bought a new stake in shares of Repligen in the second quarter valued at approximately $191,016,000. Finally, Maverick Capital Ltd. acquired a new stake in Repligen during the first quarter worth approximately $178,946,000. Institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

RGEN has been the topic of a number of recent research reports. Royal Bank Of Canada raised their price objective on Repligen from $185.00 to $200.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. upped their target price on Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Weiss Ratings lowered Repligen from a "hold (c)" rating to a "sell (d+)" rating in a report on Monday, November 2nd. Wells Fargo & Company increased their target price on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Finally, UBS Group restated a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average target price of $178.57.

Repligen Price Performance

Shares of Repligen stock traded up $1.27 on Friday, reaching $167.79. 510,110 shares of the stock were exchanged, compared to its average volume of 1,292,036. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The firm has a market cap of $10.73 billion, a PE ratio of -798.96, a P/E/G ratio of 2.85 and a beta of 1.11. The firm's 50 day moving average is $177.15 and its 200-day moving average is $145.67. Repligen Corporation has a one year low of $100.99 and a one year high of $198.87.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The business had revenue of $209.31 million for the quarter, compared to analysts' expectations of $206.70 million. During the same period last year, the firm posted $0.46 earnings per share. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. As a group, analysts anticipate that Repligen Corporation will post 2.07 EPS for the current fiscal year.

Repligen Profile

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company's offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.